Drug Profile
Research programme: drug discovery - Merck Serono/Swiss Federal Institute of Technology Lausanne
Latest Information Update: 09 Oct 2012
Price :
$50
*
At a glance
- Originator Merck Serono
- Developer Merck Serono; Swiss Federal Institute of Technology - Lausanne
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Neurological disorders
Most Recent Events
- 09 Oct 2012 No development reported for Cancer in Switzerland (unspecified route)
- 09 Oct 2012 No development reported for Neurological disorders in Switzerland (unspecified route)
- 09 Apr 2009 Research is ongoing in Switzerland